Everything we've seen

1. ·Jun 29, 12:16 PMstreamnews

   66 With $1.3 Million. Here Are 3 Hidden Gems to Target

   At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target

2. ❖Jun 29, 10:51 AMnewsvia finnhub

   66 With $1.3 Million. Here Are 3 Hidden Gems to Target

   At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target

3. ·Jun 29, 10:16 AMstreamnews

   Establishment Labs® Appoints Taylor Harris to Board of Directors

   NEW YORK, June 29, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Taylor Harris to its Board of Directors.

4. ❖Jun 29, 8:00 AMnewsvia finnhub

   Establishment Labs® Appoints Taylor Harris to Board of Directors

   NEW YORK, June 29, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Taylor Harris to its Board of Directors.

5. ?Jun 26, 3:41 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   With only 5 minutes remaining until the 3:45 PM ET forced close, there is virtually no time for the 3.54% gain to extend meaningfully to the +3% profit target from current levels. The move has largely played out intraday and the window for continuation is essentially closed. No strong catalyst headline is driving the move (the headlines are comparative/analytical pieces, not event-driven catalysts), and the macro context (low inflation expectations) is mildly supportive of duration-sensitive sectors but not a direct BMY accelerant. At this stage in the session, the risk is more likely end-of-day profit-taking or mean reversion than further extension. Probability set below 0.5 solely due to the extreme time constraint — not because the underlying move lacks conviction.

6. !Jun 26, 3:41 PMsignalseverity 0.04

   Agent 7 — Day Trader — day_trade_skipped

   With only 5 minutes remaining until the 3:45 PM ET forced close, there is virtually no time for the 3.54% gain to extend meaningfully to the +3% profit target from current levels. The move has largely played out intraday and the window for continuation is essentially closed. No strong catalyst headline is driving the move (the headlines are comparative/analytical pieces, not event-driven catalysts), and the macro context (low inflation expectations) is mildly supportive of duration-sensitive sectors but not a direct BMY accelerant. At this stage in the session, the risk is more likely end-of-day profit-taking or mean reversion than further extension. Probability set below 0.5 solely due to the extreme time constraint — not because the underlying move lacks conviction.

7. ❖Jun 26, 1:55 PMnewsvia finnhub

   Dividend Champion, Contender, And Challenger Highlights: Week Of June 28

   A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read it here.

8. ❖Jun 26, 1:01 PMnewsvia finnhub

   Why BMO's Siegerman says Merck is a top healthcare stock pick

   CNBC’s “Closing Bell Overtime” team discusses where the best opportunities are in pharma and biotech stocks with Evan Seigerman, head of healthcare research at BMO Capital Markets.

9. ❖Jun 26, 12:03 PMnewsvia finnhub

   AbbVie Stock's Growth Story Has One Question Mark

   The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.

10. ❖Jun 26, 11:50 AMnewsvia finnhub

    Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

    Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.

11. ✓Jun 26, 10:21 AMdecisionacted

    Agent 6 — Options Momentum — decide: buy

    CALL on BMY — 5-day return 5.67% with close above 20-day MA ($55.80). IV 31.2%. Sized 1 contract(s) at $2.35 premium.

12. ❖Jun 26, 7:00 AMnewsvia finnhub

    Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Play with Cautionary Notes

    Bristol-Myers Squibb offers a 4.7% dividend yield with strong profitability and value. The stock scores well on dividend and valuation ratings despite high payout ratio concerns.

13. ❖Jun 26, 3:30 AMnewsvia finnhub

    Cabaletta Bio: The Market Sold The EULAR News, I'm Buying

    Cabaletta Bio (CABA) CAR-T for autoimmune disease: EULAR 2026 data, $2.90 entry, $150M raise, 2H27 BLA path, and upside potential—read now.

14. ❖Jun 25, 12:28 PMnewsvia finnhub

    4 'Safer' Dividend Buys Out Of Barron's 23 June Better Bets Than T-Bills

    Long-term bond yields persist. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. Read which ones here.

15. ❖Jun 25, 9:10 AMnewsvia finnhub

    3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

    The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

16. ❖Jun 25, 8:15 AMnewsvia finnhub

    3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

    Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.

17. ❖Jun 25, 8:15 AMnewsvia finnhub

    Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI

    Axtria Inc., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme "Industrializing Intelligence: The Agentic Enterprise." More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed.

18. ❖Jun 25, 5:36 AMnewsvia finnhub

    Is GSK Quietly Becoming An Oncology Powerhouse

    GSK stock outlook: 3.46% dividend yield, 2026 core EPS growth guided at 7%–9%, and Exdensur as a new asthma growth driver—read the analysis now.

19. ❖Jun 25, 12:26 AMnewsvia finnhub

    Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb

    Looking back at past stock picks is important because it helps investors understand what worked, what didn’t, and why. The insurance stock is down 19% over the past year but has gained 8% over the past month.

20. ❖Jun 24, 5:00 PMnewsvia finnhub

    A $30 Billion Cancer Breakthrough Is Under Threat From Global Conflicts

    (Bloomberg) -- At the Hirslanden clinic overlooking Switzerland’s picturesque Lake Lucerne, prostate cancer patient Jörg Pegelow lies on a reclining chair as a doctor wearing two sets of gloves — one made with lead — injects a saline solution laced with a radioactive drug into a vein in his arm.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapOracle Cut 21,000 Jobs in 12 Months, Says AI Replaced

21. ❖Jun 24, 3:32 PMnewsvia finnhub

    The Number That Could Test AbbVie Stock

    AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.

22. ❖Jun 24, 10:02 AMnewsvia finnhub

    64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital

    At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at 4.50% and the 30-year at 4.94%, dividend yields have to earn their seat. The 10-year has swung between 4.43% and 4.56% in June alone, and that yield volatility is exactly what forced me to re-stack ... 64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital

23. ❖Jun 23, 10:09 PMnewsvia finnhub

    Does Bristol Myers Squibb’s 2026 Dividend and Pipeline Ambition Reframe Its Capital Priorities (BMY)?

    Bristol Myers Squibb’s board previously declared a quarterly dividend of US$0.63 per share on its common stock, payable on August 3, 2026, to shareholders of record as of July 2, 2026. This dividend decision comes as the company works to address upcoming patent expirations by advancing a broad pipeline that includes 50 compounds and multiple new medicines targeted for launch by 2030. We’ll now examine how this affirmed dividend, alongside Bristol Myers Squibb’s expanding pipeline, shapes the...

24. ▣Jun 22, 8:00 PMjournalstop

    Agent 6 — Options Momentum closed long 200 @ $1.26 (-$125.96)

    Stop: premium $1.26 ≤ trailing floor $1.42 (peak $1.89 × 0.75)

25. ❖Jun 22, 3:13 PMnewsvia finnhub

    3 Reasons to Buy Bristol Myers Squibb Stock

    Fears about a looming patent cliff have dragged on the shares.

26. ❖Jun 22, 1:00 PMnewsvia finnhub

    Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

    The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune and dermatological disorders. The introduction of novel targeted therapies such as Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), and others, and biologi

27. ❖Jun 22, 10:46 AMnewsvia finnhub

    Merck Stock’s New Drugs Were Already Answering The Big Question

    While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.

28. ❖Jun 22, 9:07 AMnewsvia finnhub

    1 S&P 500 Stock with Solid Fundamentals and 2 We Avoid

    The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

29. ?Jun 22, 7:05 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BMY is down 10.4% from its 30-day high with no confirmed fundamental catalyst (no negative SEC filings, no guidance cuts, no earnings imminent at 133 days out). The drop appears macro/sector-driven rather than company-specific — healthcare (XLV) is rank 3 of 11 by 30-day relative strength and has mild positive 30-day alpha vs. SPY, suggesting BMY's drop is idiosyncratic and warrants scrutiny. Options flow shows mildly elevated put volume (z=0.82) vs. nearly flat call volume (z=0.03), which is a modest negative signal but more likely reflects hedging than directional bearishness. There are no insider cluster buys or unusual call activity to confirm a bottom.

30. !Jun 22, 7:05 AMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BMY is down 10.4% from its 30-day high with no confirmed fundamental catalyst (no negative SEC filings, no guidance cuts, no earnings imminent at 133 days out). The drop appears macro/sector-driven rather than company-specific — healthcare (XLV) is rank 3 of 11 by 30-day relative strength and has mild positive 30-day alpha vs. SPY, suggesting BMY's drop is idiosyncratic and warrants scrutiny. Options flow shows mildly elevated put volume (z=0.82) vs. nearly flat call volume (z=0.03), which is a modest negative signal but more likely reflects hedging than directional bearishness. There are no insider cluster buys or unusual call activity to confirm a bottom.

31. ?Jun 22, 7:05 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $1.92 cash available; close=$54.00.

32. !Jun 22, 7:05 AMsignal

    Agent 5 — Dip Buyer (Evolving) — insufficient_capital

    Wanted to buy but only $1.52 cash available; close=$54.00.

33. ❖Jun 22, 6:33 AMnewsvia finnhub

    Merck's Oncology Engine Is Still Accelerating

    Merck & Co., Inc. stock outlook: FDA approves Keytruda combo for kidney cancer as sales rise. Click here for this MRK update.

34. ❖Jun 19, 9:43 AMnewsvia finnhub

    The Nasdaq 100 Has Tripled Since 2020, But These 10 Mega-Caps Are Still Underwater

    The Nasdaq 100 has tripled since 2020, but 10 mega-caps still trade below pre-Covid levels. Who's still underwater and why?

35. ❖Jun 19, 9:10 AMnewsvia finnhub

    Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

    The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

36. ❖Jun 19, 7:09 AMnewsvia finnhub

    NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?

    NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

37. ❖Jun 19, 5:13 AMnewsvia finnhub

    ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain

    RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care.

38. ❖Jun 18, 8:56 PMnewsvia finnhub

    How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story

    While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.

39. ❖Jun 18, 7:29 PMnewsvia finnhub

    Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

    Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

40. ?Jun 18, 6:21 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    The 10.4% drop from BMY's 30-day high lacks any company-specific negative catalyst in the available evidence — no earnings misses, guidance cuts, pipeline failures, or adverse SEC filings are present. The macro context shows a flattening yield curve (T10Y2Y at 3.5σ below trend), which tends to favor defensive sectors like large-cap pharma, suggesting the sell-off may be sector-rotation or broader risk-off pressure rather than fundamental deterioration. BMY remains a financially diversified large-cap biopharma with significant cash flows, but the absence of recent filings and minimal news coverage limits conviction in a near-term catalyst for recovery.

41. !Jun 18, 6:21 PMsignalseverity 0.10

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    The 10.4% drop from BMY's 30-day high lacks any company-specific negative catalyst in the available evidence — no earnings misses, guidance cuts, pipeline failures, or adverse SEC filings are present. The macro context shows a flattening yield curve (T10Y2Y at 3.5σ below trend), which tends to favor defensive sectors like large-cap pharma, suggesting the sell-off may be sector-rotation or broader risk-off pressure rather than fundamental deterioration. BMY remains a financially diversified large-cap biopharma with significant cash flows, but the absence of recent filings and minimal news coverage limits conviction in a near-term catalyst for recovery.

42. ?Jun 18, 6:05 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BMY is down 10.4% from its 30-day high with no confirmed fundamental catalyst (no negative SEC filings, no guidance cuts, no earnings imminent at 133 days out). The drop appears macro/sector-driven rather than company-specific — healthcare (XLV) is rank 3 of 11 by 30-day relative strength and has mild positive 30-day alpha vs. SPY, suggesting BMY's drop is idiosyncratic and warrants scrutiny. Options flow shows mildly elevated put volume (z=0.82) vs. nearly flat call volume (z=0.03), which is a modest negative signal but more likely reflects hedging than directional bearishness. There are no insider cluster buys or unusual call activity to confirm a bottom.

43. !Jun 18, 6:05 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BMY is down 10.4% from its 30-day high with no confirmed fundamental catalyst (no negative SEC filings, no guidance cuts, no earnings imminent at 133 days out). The drop appears macro/sector-driven rather than company-specific — healthcare (XLV) is rank 3 of 11 by 30-day relative strength and has mild positive 30-day alpha vs. SPY, suggesting BMY's drop is idiosyncratic and warrants scrutiny. Options flow shows mildly elevated put volume (z=0.82) vs. nearly flat call volume (z=0.03), which is a modest negative signal but more likely reflects hedging than directional bearishness. There are no insider cluster buys or unusual call activity to confirm a bottom.

44. ?Jun 18, 6:04 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $1.52 cash available; close=$54.00.

45. ❖Jun 18, 4:57 PMnewsvia finnhub

    What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine?

    The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.

46. ❖Jun 18, 2:03 PMnewsvia finnhub

    Kardigan shares soar after Nasdaq debut

    Investing.com -- Kardigan Inc. shares rose iver 27% roughly one hour into its Nasdaq debut on Thursday, after the heart-health focused biotech raised $400 million in an initial public offering.

47. ❖Jun 18, 1:54 PMnewsvia finnhub

    Surge in biotech being driven by M&A, says UBS's Michael Yee

    Michael Yee, UBS global head of biotech research, joins 'Fast Money' to talk the biotech sector.

48. ✓Jun 18, 10:20 AMdecisionacted

    Agent 6 — Options Momentum — decide: buy

    PUT on BMY — 5-day return -5.08% with close below 20-day MA ($56.49). IV 29.7%. Sized 2 contract(s) at $1.89 premium.

49. ❖Jun 18, 6:59 AMnewsvia finnhub

    Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

    PRINCETON, N.J., June 18, 2026--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

50. ▢Jun 17, 8:00 PMjournal

    Agent 6 — Options Momentum opened long 200 @ $1.89

51. ❖Jun 17, 7:20 PMnewsvia finnhub

    Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes

    Bristol-Myers Squibb (BMY) stock is drawing attention after recent trading performance, with shares closing at US$55.28. Investors are weighing this level against the company’s mixed growth profile across revenue, earnings and longer term returns. See our latest analysis for Bristol-Myers Squibb. Recent trading has been a bit soft, with a 30 day share price return down 3.54% and a 90 day return down 4.87%. However, the 1 year total shareholder return of 23.92% shows that longer term holders...

52. ❖Jun 17, 6:15 PMnewsvia finnhub

    Bristol Myers Squibb (BMY) Unveils Myeloma Trial Win And New Gulf Leadership

    Bristol Myers Squibb (NYSE:BMY) reported positive Phase III SUCCESSOR-2 trial results in multiple myeloma at a major medical conference. The company highlighted early clinical success for a new CAR T-cell therapy targeting blood cancers. Bristol Myers Squibb appointed a new General Manager to lead its operations across the Gulf region. Bristol Myers Squibb is a large biopharmaceutical company with a long-standing focus on oncology and hematology treatments. The fresh readout from the...

53. ❖Jun 17, 5:45 PMnewsvia finnhub

    Bristol Myers Squibb (BMY) Stock Moves -1.14%: What You Should Know

    The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.28, representing a -1.14% change from its previous close.

54. ❖Jun 17, 4:16 PMnewsvia finnhub

    Bristol Myers Squibb Announces Dividend

    PRINCETON, N.J., June 17, 2026--Bristol Myers Squibb Announces Dividend

55. ❖Jun 17, 11:15 AMnewsvia finnhub

    CTD-ILD Enters New Treatment Era, but Physicians Still See Significant Unmet Need

    Only 15% of CTD-ILD patients achieve drug-free remission, fueling interest in Bristol Myers Squibb's zola-cel, GSK's Benlysta, and next-generation antifibrotics.Exton, PA, June 17, 2026 (GLOBE NEWSWIRE) -- Despite the introduction of new therapies, connective tissue disease-associated interstitial lung disease (CTD-ILD) remains an area of significant unmet need, according to findings from the recently updated Special Topix™: ILD in Rheumatology (US) study from Spherix Global Insights. Physicians

56. ❖Jun 17, 10:54 AMnewsvia finnhub

    Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?

    CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.

57. ❖Jun 17, 9:59 AMnewsvia finnhub

    Is it a Good Idea to Invest in Immunocore Stock Right Now?

    IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.

58. ❖Jun 17, 9:00 AMnewsvia finnhub

    Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

    Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

59. ❖Jun 17, 8:43 AMnewsvia finnhub

    Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug

    Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination studies after mixed Phase 2 results.

60. ❖Jun 17, 6:32 AMnewsvia finnhub

    EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

    Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline candidates in multiple myeloma (MM) at the European Hematology Association Congress (EHA) 2026, held from June 11–14. While the drugmaker already has multiple therapies approved for the type of blood cancer, BMS is hoping to expand its presence in the market by addressing certain…

61. ❖Jun 17, 6:15 AMnewsvia finnhub

    Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries

    Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has appointed Mayada Al-Ahmad to the position of General Manager of Saudi Arabia and Gulf Countries effective June 1, 2026. In this role, Mayada will lead the affiliate spanning Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan, with responsibility for advancing BMS's mission to deliver transformative medicines to patients across the region.

62. ❖Jun 17, 5:17 AMnewsvia finnhub

    Bristol Myers Squibb Announces Updated Guidance For BREYANZI Chimeric Antigen Receptor T Cell Therapy Includes Lowered Recommended Duration For Patients To Remain In Close Proximity To Specialized Treatment Centre From 28 Days To 14 Days

    Bristol Myers Squibb Canada (BMS) is pleased to announce an update to the Canadian product monograph for BREYANZI® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor T (CAR T) cell therapy,

63. ❖Jun 16, 2:18 PMnewsvia finnhub

    Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?

    Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

64. ❖Jun 16, 9:29 AMnewsvia finnhub

    Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?

    Edgewise Therapeutics shares yo-yoed Tuesday as investors compared the results of its experimental heart disease treatment to approved drugs.

65. ❖Jun 16, 6:35 AMnewsvia finnhub

    3 Dividend Stocks to Hold for the Long Haul

    They have a habit of consistently raising their payouts.

66. ❖Jun 16, 6:12 AMnewsvia finnhub

    SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It

    Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet tells a different story. SCHD’s top 10 holdings now account for 41% of the fund’s $71.6 billion in net assets, well above the roughly 30% top-10 weight typical of large-cap dividend peers. SCHD still earns ... SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It

67. ?Jun 8, 3:36 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 10 minutes remaining until the forced 3:45 PM ET close, there is minimal runway for further downside continuation. BMY has already moved -2.27%, which is a meaningful intraday move, but at this stage late-session dynamics (covering, rebalancing, mean-reversion flows) tend to dominate over momentum. The macro context (T10Y2Y at 0.38, 2.5σ below trend) is modestly supportive of defensives like BMY — a bear-flattening environment can actually provide a slight tailwind to pharma/defensive names, adding a mild counter-pressure to the existing downside move. No catalytic headlines are present to explain the move or sustain it further. With the extreme time constraint and a slight macro lean favoring defensives, the probability of meaningful additional downside in the final 10 minutes is below the action threshold.

68. !Jun 8, 3:36 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    With only 10 minutes remaining until the forced 3:45 PM ET close, there is minimal runway for further downside continuation. BMY has already moved -2.27%, which is a meaningful intraday move, but at this stage late-session dynamics (covering, rebalancing, mean-reversion flows) tend to dominate over momentum. The macro context (T10Y2Y at 0.38, 2.5σ below trend) is modestly supportive of defensives like BMY — a bear-flattening environment can actually provide a slight tailwind to pharma/defensive names, adding a mild counter-pressure to the existing downside move. No catalytic headlines are present to explain the move or sustain it further. With the extreme time constraint and a slight macro lean favoring defensives, the probability of meaningful additional downside in the final 10 minutes is below the action threshold.

69. ?Jun 5, 9:15 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BMY is up 3.44% intraday with no attributable headline, suggesting institutional flow or sector rotation into defensives. The macro context shows T10Y2Y at 1.9σ below trend (mild flattening), which historically supports defensive/pharma names like BMY as investors seek yield and safety — a modest tailwind. With 390 minutes remaining (roughly 6.5 hours, implying this is early-to-mid session), there is ample time for the move to extend. No reversal signals or fade pattern is evident from available data. However, the absence of a catalyst and no volume confirmation data tempers conviction. The macro read is supportive but not strongly so. Assigning a modest continuation probability above the 0.5 threshold given: (1) meaningful 3%+ move indicating real size/flow, (2) defensive sector macro tailwind, (3) substantial time remaining, offset by (4) no headline catalyst and (5) no volume data to confirm institutional accumulation.

70. !Jun 5, 9:15 AMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    BMY is up 3.44% intraday with no attributable headline, suggesting institutional flow or sector rotation into defensives. The macro context shows T10Y2Y at 1.9σ below trend (mild flattening), which historically supports defensive/pharma names like BMY as investors seek yield and safety — a modest tailwind. With 390 minutes remaining (roughly 6.5 hours, implying this is early-to-mid session), there is ample time for the move to extend. No reversal signals or fade pattern is evident from available data. However, the absence of a catalyst and no volume confirmation data tempers conviction. The macro read is supportive but not strongly so. Assigning a modest continuation probability above the 0.5 threshold given: (1) meaningful 3%+ move indicating real size/flow, (2) defensive sector macro tailwind, (3) substantial time remaining, offset by (4) no headline catalyst and (5) no volume data to confirm institutional accumulation.

71. ❖Jun 4, 1:25 PMnewsvia finnhub

    REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

    Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

72. ?Jun 4, 9:36 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BMY is up 2.38% today, a meaningful intraday move suggesting real buying interest. Headlines are mildly constructive (dividend comparison favoring BMY, cancer drug pipeline coverage) but neither is a strong catalyst. The macro context shows a flat/modestly inverted curve (T10Y2Y at 0.41, 2.1σ below trend) which tends to favor defensives like BMY — supportive but not a strong tailwind. With 370 minutes remaining there is ample time for continuation. No clear reversal signals or fade pattern described. The move is borderline — not driven by a single explosive catalyst, but real flow is present and defensives benefit from the macro backdrop. Probability sits just above 0.5 reflecting ordinary momentum with no strong reason to fade, but no high-conviction continuation signal either.

73. !Jun 4, 9:36 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    BMY is up 2.38% today, a meaningful intraday move suggesting real buying interest. Headlines are mildly constructive (dividend comparison favoring BMY, cancer drug pipeline coverage) but neither is a strong catalyst. The macro context shows a flat/modestly inverted curve (T10Y2Y at 0.41, 2.1σ below trend) which tends to favor defensives like BMY — supportive but not a strong tailwind. With 370 minutes remaining there is ample time for continuation. No clear reversal signals or fade pattern described. The move is borderline — not driven by a single explosive catalyst, but real flow is present and defensives benefit from the macro backdrop. Probability sits just above 0.5 reflecting ordinary momentum with no strong reason to fade, but no high-conviction continuation signal either.

74. ▣Jun 3, 8:00 PMjournalstop

    Agent 6 — Options Momentum closed long 500 @ $0.65 (-$343.51)

    Stop: premium $0.65 ≤ trailing floor $1.16 (peak $1.55 × 0.75)

75. ?Jun 3, 10:37 AMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    The 10.6% drop from the 30-day high appears to reflect macro/sector rotation pressure rather than company-specific deterioration — no earnings warnings, guidance cuts, or accounting issues are evident in the available news or filings. BMY is a high-yield defensive name, and the yield-curve environment (T10Y2Y at 2σ below trend, bear-flattening) favors defensives in some scenarios but also creates uncertainty around rate-sensitive valuations. The neutral-sentiment headlines comparing BMY to peers suggest the move is more relative-value rotation than fundamental breakdown.

76. !Jun 3, 10:37 AMsignalseverity 0.10

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    The 10.6% drop from the 30-day high appears to reflect macro/sector rotation pressure rather than company-specific deterioration — no earnings warnings, guidance cuts, or accounting issues are evident in the available news or filings. BMY is a high-yield defensive name, and the yield-curve environment (T10Y2Y at 2σ below trend, bear-flattening) favors defensives in some scenarios but also creates uncertainty around rate-sensitive valuations. The neutral-sentiment headlines comparing BMY to peers suggest the move is more relative-value rotation than fundamental breakdown.

77. ?Jun 3, 10:36 AMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    The 10.6% drop from the 30-day high appears to reflect macro/sector rotation pressure rather than company-specific deterioration — no earnings warnings, guidance cuts, or accounting issues are evident in the available news or filings. BMY is a high-yield defensive name, and the yield-curve environment (T10Y2Y at 2σ below trend, bear-flattening) favors defensives in some scenarios but also creates uncertainty around rate-sensitive valuations. The neutral-sentiment headlines comparing BMY to peers suggest the move is more relative-value rotation than fundamental breakdown.

78. ?Jun 3, 7:02 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $2.42 cash available; close=$54.46.

79. !Jun 3, 7:02 AMsignal

    Agent 5 — Dip Buyer (Evolving) — insufficient_capital

    Wanted to buy but only $8.58 cash available; close=$54.45.

80. ?Jun 3, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $5.86 cash available; close=$54.46.

81. !Jun 3, 7:02 AMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    Wanted to buy but only $22.75 cash available; close=$54.45.

82. ?Jun 2, 6:04 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash

    Wanted to buy but only $22.75 cash available; close=$54.45.

83. ?Jun 2, 6:04 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $8.58 cash available; close=$54.45.

84. !Jun 2, 6:04 PMsignal

    Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital

    BMY's 10.4% dip from its 30-day high appears macro/sector-driven rather than company-specific, as the Health Care sector has underperformed SPY by ~7.87pts over 30 days, suggesting the stock is caught in a broader sector rotation. The EU label expansion for Opdivo is a tangible positive catalyst indicating pipeline progress, and the unusually bullish options flow (call volume z-score of +8.61 vs. near-neutral put volume) strongly suggests informed buyers are accumulating on this dip. With earnings 149 days away, there is no imminent binary risk, and the macro environment (VIX at 24th percentile, normal yield curve) is relatively benign.

85. !Jun 2, 6:04 PMsignal

    Agent 5 — Dip Buyer (Evolving) — insufficient_capital

    Net signal score: +3. No hard veto applies — earnings are 149 days away (well clear of the 14/30-day thresholds), no SEC filings reveal fundamental deterioration, and no going-concern or guidance-cut language is present. Positive signals: (1) Extremely unusual call volume (z=+8.61) on a dipping stock is a strong informed-buying signal (+1); (2) the health care sector is underperforming the market meaningfully (−7.87pts vs SPY over 30 days), suggesting this is sector-wide rather than idiosyncratic (+1); (3) no earnings within 30 days provides a clean runway for rebound (+1). The EU label expansion for Opdivo is a mild incremental positive catalyst. Soft negatives: the 10Y at 4.47% is near but not above the 4.5% threshold, so neutral for a value/defensive pharma name like BMY; VIX at the 24th percentile is benign; the 2s10s spread is positive (+0.42pp), so no curve inversion penalty. No insider activity (neither positive nor negative). Net score of +3 with no veto supports a buy at the upper end of the +2 range given the unusually strong call flow signal.

86. ✓Jun 1, 6:02 PMdecisionacted

    Agent 6 — Options Momentum — decide: buy

    PUT on BMY — 5-day return -7.61% with close below 20-day MA ($57.17). IV 21.7%. Sized 5 contract(s) at $1.33 premium.

87. ▢May 31, 8:00 PMjournal

    Agent 6 — Options Momentum opened long 500 @ $1.33

88. ?May 22, 9:15 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BMY is up 1.73% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. The move is below the 2-5% threshold of strong conviction, so it reads as moderate momentum. With 390 minutes remaining (well before the 3:45 ET cutoff), there is ample time for continuation. The macro context shows T10Y3M at 2.2σ above trend — a steepening yield curve environment that typically pressures recession-sensitive and defensive sectors like large-cap pharma (BMY). This creates a mild headwind, as capital may rotate away from defensives toward rate-beneficiary sectors. However, the absence of negative news and the positive price action itself provide a baseline momentum case. No reversal pattern or volume concern is flagged. Net assessment: modest upward continuation bias, tempered by the macro yield curve backdrop being mildly unfavorable for BMY's defensive pharma profile. Probability sits just above the trigger threshold.

89. !May 22, 9:15 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    BMY is up 1.73% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. The move is below the 2-5% threshold of strong conviction, so it reads as moderate momentum. With 390 minutes remaining (well before the 3:45 ET cutoff), there is ample time for continuation. The macro context shows T10Y3M at 2.2σ above trend — a steepening yield curve environment that typically pressures recession-sensitive and defensive sectors like large-cap pharma (BMY). This creates a mild headwind, as capital may rotate away from defensives toward rate-beneficiary sectors. However, the absence of negative news and the positive price action itself provide a baseline momentum case. No reversal pattern or volume concern is flagged. Net assessment: modest upward continuation bias, tempered by the macro yield curve backdrop being mildly unfavorable for BMY's defensive pharma profile. Probability sits just above the trigger threshold.

90. ?May 19, 2:20 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BMY is up 1.54% intraday, a moderate but meaningful move suggesting real buying flow. No news headlines are present to attribute a catalyst, but absence of news does not negate momentum. The macro context shows 10Y inflation expectations elevated at 2.4σ above trend — BMY as a large-cap pharma/healthcare name is relatively defensive and less duration-sensitive, meaning the macro headwind is limited. With 85 minutes remaining there is reasonable time for continuation, though not ample runway for a full extension. The move is below the 2% threshold that would indicate strong conviction, and with no news catalyst the risk of afternoon fade is real. Overall, the setup is modestly favorable for continuation with no clear reversal signal, warranting a slight lean toward up but without high conviction.

91. !May 19, 2:20 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    BMY is up 1.54% intraday, a moderate but meaningful move suggesting real buying flow. No news headlines are present to attribute a catalyst, but absence of news does not negate momentum. The macro context shows 10Y inflation expectations elevated at 2.4σ above trend — BMY as a large-cap pharma/healthcare name is relatively defensive and less duration-sensitive, meaning the macro headwind is limited. With 85 minutes remaining there is reasonable time for continuation, though not ample runway for a full extension. The move is below the 2% threshold that would indicate strong conviction, and with no news catalyst the risk of afternoon fade is real. Overall, the setup is modestly favorable for continuation with no clear reversal signal, warranting a slight lean toward up but without high conviction.

92. ?May 19, 12:50 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BMY is up 1.55% with 175 minutes remaining — a moderate move with meaningful time left in the session. There are no recent headlines driving the move, which suggests either quiet accumulation or sector rotation rather than a catalyst-driven spike prone to fade. The macro context shows elevated 10-year inflation expectations (T10YIE at 2.4σ above trend), which pressures long-duration sensitive sectors; however, BMY as a large-cap pharma/defensive name is relatively insulated from rate-duration dynamics compared to tech or utilities. Pharma can actually attract defensive rotation in risk-off macro environments. The move is below the 2% threshold where I'd have higher conviction in momentum continuation, and the absence of any news catalyst limits my ability to assess whether there's a fundamental driver sustaining the bid. No reversal signals are evident from the data provided. Overall, this is a borderline setup — mild positive momentum, defensive sector characteristics that are macro-neutral to slightly favorable, and sufficient time remaining — warranting a slight lean toward continuation but without strong conviction.

93. !May 19, 12:50 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    BMY is up 1.55% with 175 minutes remaining — a moderate move with meaningful time left in the session. There are no recent headlines driving the move, which suggests either quiet accumulation or sector rotation rather than a catalyst-driven spike prone to fade. The macro context shows elevated 10-year inflation expectations (T10YIE at 2.4σ above trend), which pressures long-duration sensitive sectors; however, BMY as a large-cap pharma/defensive name is relatively insulated from rate-duration dynamics compared to tech or utilities. Pharma can actually attract defensive rotation in risk-off macro environments. The move is below the 2% threshold where I'd have higher conviction in momentum continuation, and the absence of any news catalyst limits my ability to assess whether there's a fundamental driver sustaining the bid. No reversal signals are evident from the data provided. Overall, this is a borderline setup — mild positive momentum, defensive sector characteristics that are macro-neutral to slightly favorable, and sufficient time remaining — warranting a slight lean toward continuation but without strong conviction.

94. ?May 19, 10:56 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BMY is up 1.68% today, a modest but real move suggesting genuine buying interest. No news catalyst is identifiable, but absence of news doesn't disqualify continuation — this could be sector rotation or institutional accumulation. Macro context shows elevated 10Y inflation expectations (2.48, +2.4σ above trend), which is a mild headwind for long-duration sensitive sectors, but pharma/healthcare (BMY) is less rate-sensitive than utilities or REITs, so the macro drag is limited. With 289 minutes remaining there is ample time for the move to extend. The move magnitude (1.68%) is below the 2-5% high-conviction range, so momentum signal is moderate rather than strong. No reversal pattern is evident. On balance, a slight lean toward continuation with no strong reason to fade — probability just above the 0.5 threshold.

95. !May 19, 10:56 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    BMY is up 1.68% today, a modest but real move suggesting genuine buying interest. No news catalyst is identifiable, but absence of news doesn't disqualify continuation — this could be sector rotation or institutional accumulation. Macro context shows elevated 10Y inflation expectations (2.48, +2.4σ above trend), which is a mild headwind for long-duration sensitive sectors, but pharma/healthcare (BMY) is less rate-sensitive than utilities or REITs, so the macro drag is limited. With 289 minutes remaining there is ample time for the move to extend. The move magnitude (1.68%) is below the 2-5% high-conviction range, so momentum signal is moderate rather than strong. No reversal pattern is evident. On balance, a slight lean toward continuation with no strong reason to fade — probability just above the 0.5 threshold.